1. When switching to insulin glargine U300 from twice daily insulin NPH, the daily dose of the new basal insulin should be _________.

2. Compared with insulin glargine U100, insulin degludec U100 has ________.

3. Compared with adding prandial insulin, adding a GLP-1 receptor agonist to a basal insulin regimen for a patient with T2DM who has an A1c value of 7.7% is likely to produce each of the following clinical outcomes EXCEPT_________.

4. Which of the following GLP-1 receptor agonists has been combined with a basal insulin analog in a fixed-dose, 2-drug formulation that has been recommended for approval by a US Food and Drug Administration advisory committee for the treatment of patients with T2DM?

5. A 55-year-old woman with T2DM (current A1c, 7.1%) who recently lost 10% of her body weight comes to an appointment complaining of 3 instances of low blood sugar over the last week. These hypoglycemic episodes are confirmed by her daily blood glucose log. She is being treated with metformin 1000 mg twice daily and insulin glargine 20 units each morning. After completing the enduring educational program, which of the following potential changes to her treatment regimen are you NOW most likely to recommend?

« Return to Activity